HEPA Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -87.96%. Hepion Pharmaceuticals's return on equity of -- beat Fortress Biotech's return on equity of --.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 130334.78%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 823.7%. Given that Hepion Pharmaceuticals has higher upside potential than Fortress Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Fortress Biotech.

Hepion Pharmaceuticals has a beta of 1.625, which suggesting that the stock is 62.537% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.750, suggesting its more volatile than the S&P 500 by 74.992%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Hepion Pharmaceuticals's net income of -$4.9M is higher than Fortress Biotech's net income of -$12.9M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.32x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -6391.57%. Hepion Pharmaceuticals's return on equity of -- beat Janux Therapeutics's return on equity of -11.37%.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 130334.78%. On the other hand Janux Therapeutics has an analysts' consensus of $87.85 which suggests that it could grow by 186.33%. Given that Hepion Pharmaceuticals has higher upside potential than Janux Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Janux Therapeutics.

Hepion Pharmaceuticals has a beta of 1.625, which suggesting that the stock is 62.537% more volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Janux Therapeutics quarterly revenues of $439K. Hepion Pharmaceuticals's net income of -$4.9M is higher than Janux Therapeutics's net income of -$20.2M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 126.36x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -49.65%. Hepion Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 130334.78%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that Hepion Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Hepion Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Hepion Pharmaceuticals has a beta of 1.625, which suggesting that the stock is 62.537% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Hepion Pharmaceuticals's net income of -$4.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 2.31%. Hepion Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.91%.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 130334.78%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Hepion Pharmaceuticals has higher upside potential than Pfizer, analysts believe Hepion Pharmaceuticals is more attractive than Pfizer.

Hepion Pharmaceuticals has a beta of 1.625, which suggesting that the stock is 62.537% more volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Hepion Pharmaceuticals's net income of -$4.9M is lower than Pfizer's net income of $410M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.